The Advances in Chronic Hepatitis C: Management and Treatment program is a comprehensive, expert review of the 67th American Association for the Study of the Liver Diseases Annual Meeting (AASLD 2016). This program consists of four components: (1) CME Internet Symposium: AASLD 2016 Review: a 1.5 hour Internet symposium that features an overview and discussion of key presentations and posters, selected by the expert faculty discussants; (2) Comprehensive Expert Review and Discussion of Key Presentations: an on-line, in-depth review of 8 of the key poster/presentations reviewed in the Internet symposium; (3) Rapid-Fire Review of AASLD 2016: a podcast that provides a brief, audio summary of the most essential data presented at the conference; and (4) From Conference to Clinic: Reviewing and Applying Data from AASLD 2016: case-based dinner meetings during which the key data from AASLD 2016 are reviewed, discussed and applied to patient care.
From Conference to Clinic: Reviewing and Applying Data From AASLD 2016 is an interactive, case-based dinner program series designed to highlight and discuss the clinical significance and application of new findings in HCV medicine presented at AASLD 2016. Because the focus of the dinner programs will be on case studies and applying the data presented at AASLD 2016 in a clinical setting, prior to attending a dinner program participants will be asked to view the CME Internet Symposium: AASLD 2016 Review, which will familiarize them with the AASLD 2016 data and serve as a comprehensive conference overview and summary. As a result of this blended learning approach, participants will gain an increased understanding of key data presented at AASLD 2016 and be better prepared to address their HCV patients' health needs and provide optimal care in a clinical setting.
All online components of the program will be accessible at www.viraled.com
This program is produced by the Postgraduate Institute for Medicine and ViralEd, Inc. It is not a session created by or presented at AASLD 2016 and it is not sanctioned by the organizers of AASLD 2016.
This activity has been designed to meet the educational needs of physicians, physician assistants, advanced practice nurses and other health care professionals involved in the care of patients with HCV infection.
After completing this activity, the participant should be better able to:
|
Tuesday, November 29, 2016 Los Angeles, CA |
Tuesday, December 6, 2016 Miami, FL |
| Wednesday, November 30, 2016 New York, NY |
|
| Maurizio Bonacini, MD Director, HIV-Liver Clinic Department of Transplantation California Pacific Medical Center San Francisco, California |
Sammy Saab, MD |
John M. Vierling, MD Professor of Medicine Professor of Surgery Chief of Hepatology Director of Advanced Liver Therapies St. Luke’s Hospital Director of Baylor Liver Health Houston, Texas |
| Lennox Jeffers, MD Chief of Hepatology Miami VA Medical Center Associate Chief Center for Liver Disease Professor of Medicine University of Miami’s School of Medicine Miami, Florida |
Mark Sulkowski, MD Professor of Medicine and Medical Director Viral Hepatitis Center Johns Hopkins University School of Medicine Baltimore, Maryland |
6:00 - 6:30 PM: Check-in/Walk-in Registration
6:30 - 8:30 PM: Program and Q&A
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and ViralEd, Inc. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Postgraduate Institute for Medicine designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
As of August 1, 2013, pharmaceutical companies are required by the open payments act (AKA Sunshine Act) to account for certain transfers of value provided to physicians. The federal guidance for the Sunshine Act provides exceptions for CME expenses that meet certain criteria. We believe the program to which you are invited meets these exce ptions, and therefore we will not be collecting, nor reporting, any information gathered from this program. If federal guidance is further clarified in the future, we will then pro vide that information to the supporting pharmaceutical companies to the best of our ability.
The Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or ap parent conflict of interest (COI) they may have as related to th e content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.
This activity is supported by an independent educational grant from Gilead Sciences Medical Affairs.
This coverage is not sanctioned by the conference organizers and is not an official part of the conference proceedings.
